Advertisement

Topics

FDA Grants Breakthrough Therapy Designation for Alnylam's Givosiran for the Prophylaxis of Attacks in Patients with Acute Hepatic Porphyria

23:06 EDT 30 May 2017 | Drugs.com

CAMBRIDGE, Mass.--(BUSINESS WIRE) May 31, 2017 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has received Breakthrough Therapy designation from the U.S. Food and Drug Administration...

Original Article: FDA Grants Breakthrough Therapy Designation for Alnylam's Givosiran for the Prophylaxis of Attacks in Patients with Acute Hepatic Porphyria

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Breakthrough Therapy Designation for Alnylam's Givosiran for the Prophylaxis of Attacks in Patients with Acute Hepatic Porphyria"

Advertisement
Quick Search
Advertisement
Advertisement